When Was NeoFipronis (Pronidesivir) Launched on the Market
NeoFipronis (Pronidesivir) was officially launched on the market in March 2026, after receiving formal approval from the Laos Ministry of Agriculture and Forestry (MAF) and obtaining an official drug registration number. This milestone made NeoFipronis the world’s first officially registered oral FIP treatment with a formal market launch status, giving cat owners and veterinarians a new option for managing feline infectious peritonitis (FIP) with greater convenience and confidence.
Feline infectious peritonitis is one of the most serious diseases affecting cats, and it can progress quickly if not treated in time. Common signs include loss of appetite, lethargy, fever, abdominal fluid buildup, pleural effusion, enlarged lymph nodes, inflammatory granulomas, neurological damage, and uveitis. These symptoms often appear in wet, dry, ocular, or neurological forms of FIP, making early recognition and prompt treatment especially important for improving outcomes.
The active ingredient in NeoFipronis (Pronidesivir) is GS-441524, a compound that has been extensively studied and validated through clinical practice for its antiviral performance against FIP. As an oral therapy, NeoFipronis offers several practical advantages: it is non-invasive, rapidly absorbed, fast-acting, well tolerated, and associated with relatively few side effects. For many cat owners, this makes daily treatment much easier to manage compared with injectable alternatives.
For dosing, NeoFipronis is generally given according to body weight at 15 mg per kilogram once daily, which is equivalent to half a tablet per kilogram based on the common formulation. For neurological or ocular FIP, veterinarians may recommend increasing the dose to 30 mg/kg, depending on the cat’s condition and response to treatment. It is usually best administered on an empty stomach, either one hour before meals or two hours after eating, to support absorption. Treatment should be continued for no less than 12 weeks, and doses should not be missed.
During treatment, it is important to watch for changes in appetite, body temperature, energy level, and overall behavior. Regular follow-up testing for blood parameters, liver function, and kidney function is also recommended, especially for cats with more advanced disease or complications. Although NeoFipronis is described as an over-the-counter product, using it under veterinary guidance is still strongly advised to help ensure correct dosing and proper monitoring. This product is for cats only and not for human use.
For product authenticity and quality assurance, buyers should check the official NeoFipronis website and confirm the registration details before purchase. As a market-launched oral FIP medication with official approval in Laos, NeoFipronis (Pronidesivir) has become an important name in modern feline infectious peritonitis care, especially for cat owners seeking a practical, science-based treatment option for FIP symptoms and long-term recovery support.
